Patents by Inventor Gemma Packer

Gemma Packer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fluorinated bile acid derivatives
    Patent number: 11517577
    Abstract: The invention relates to compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; and liver damage arising from fibrosis.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: December 6, 2022
    Assignees: NZP UK LIMITED, THE UNIVERSITY OF SOUTHAMPTON
    Inventors: Alexander Charles Weymouth-Wilson, Gemma Packer, Bruno Jan Pol Linclau, Dannielle Kydd-Sinclair, Kimberly Ann Watson
  • FLUORINATED BILE ACIDS
    Publication number: 20220073557
    Abstract: Compounds of general formula (1): wherein R1, R2 and R3 are as defined herein; are of use in the treatment and prevention of neurodegenerative disorders including Alzheimer's disease and Parkinson's disease.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Applicants: NZP UK LIMITED, THE UNIVERSITY OF SOUTHAMPTON
    Inventors: Alexander Charles Weymouth-Wilson, Bruno Jan Pol Linclau, Gemma Packer, Joseph Watts, Heather Mortiboys, Oliver Bandmann, Christopher Hastings
  • FLUORINATED BILE ACID DERIVATIVES
    Publication number: 20210299148
    Abstract: The invention relates to compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; and liver damage arising from fibrosis.
    Type: Application
    Filed: July 30, 2019
    Publication date: September 30, 2021
    Applicants: NZP UK LIMITED, THE UNIVERSITY OF SOUTHAMPTON
    Inventors: Alexander Charles Weymouth-Wilson, Gemma Packer, Bruno Jan Pol Linclau, Dannielle Kydd-Sinclair, Kimberly Ann Watson